MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.96 -0.06 (-0.21%)
Official Closing Price Updated: 7:00 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable. 
Via The Motley Fool
News headline image
2 Cash-Producing Stocks with Solid Fundamentals and 1 We Turn Down
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax ↗
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions. 
Via Benzinga
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
The Most Concerning Thing About Pfizer's Dividend Isn't What You Think ↗
Pfizer's payout ratio is above 100%, but that's not the number you should probably be watching right now. 
Via The Motley Fool
Topics Intellectual Property
Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
My 2 Favorite Dividend Stocks to Buy in August ↗
These are two stocks that pay investors a regular income. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
These healthcare leaders are unlikely to suspend their dividend programs. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
D-Wave Quantum vs. Rigetti Computing: Which Quantum Computing Stock Is a Better Investment in 2026? ↗
While both D-Wave and Rigetti's revenues have been volatile, their valuations tell a starkly different story for quantum investors. 
Via The Motley Fool
News headline image
Prediction: This Is Where Pfizer Stock Will Be in 2030 ↗
Pfizer is facing material patent expirations over the next two years, but that will be over by 2030. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Dividend ETF That Generates Passive Income While You Sleep ↗
Income generation is more about finding consistency than finding an ultra-high yield. 
Via The Motley Fool
Topics ETFs
News headline image
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
2 Reasons to Watch PFE and 1 to Stay Cautious
Pfizer has been treading water for the past six months, recording a small return of 2.6% while holding steady at $27.76. The stock also fell short of the S&P... 
Via StockStory
Topics Supply Chain
News headline image
1 S&P 500 Stock to Research Further and 2 That Underwhelm
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight ↗
Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results. 
Via Benzinga
News headline image
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript ↗
CEO Rajavelu discusses $105 million financing and SP001 immunology strategy. 
Via The Motley Fool
Topics Earnings
News headline image
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data ↗
Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission. 
Via The Motley Fool
Topics Stocks
News headline image
Why Pfizer (PFE) Stock Is Trading Up Today
What Happened? Shares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial results from peer... 
Via StockStory
Topics World Trade
News headline image
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions ↗
Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race. 
Via Benzinga
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
Pfizer Stock Rises Wednesday: What's Going On? ↗
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that... 
Via Benzinga
News headline image
Protalix (PLX) Q2 2026 Earnings Call Transcript ↗
Elfabrio sales surge drives $19.9M quarterly revenue and $22.1M H1 net income. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
3 S&P 500 Stocks We Keep Off Our Radar
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Fraud Stocks
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Warren Buffett and Greg Abel Keep Overlooking This Stock -- but It's One of the Most Berkshire-Ready Picks on the Market ↗
Even if Berkshire Hathaway never scoops up a stake on this largely overlooked and mostly unloved name, that doesn't mean it doesn't have a place in your portfolio. 
Via The Motley Fool
News headline image
2 Profitable Stocks with Solid Fundamentals and 1 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story